Literature DB >> 21252667

Anaplastic thyroid carcinoma: palliation or treatment?

Richard O Wein1, Randal S Weber.   

Abstract

PURPOSE OF REVIEW: To review the recent published literature on the topic of anaplastic thyroid carcinoma and discern if significant advances have occurred that alter the historically poor prognosis associated with this diagnosis. RECENT
FINDINGS: Surgical resection for patients with stage IVA disease (intra-thyroidal without extracapsular extension) with postoperative chemoradiation remains the standard recommendation. Care for patients with stage IVB disease, extrathyroidal spread without distant metastases, remains varied and controversial. Research into different molecular therapies (deacetylase inhibitors, tubulin binding compounds, etc.) and the pathogenesis of anaplastic carcinoma continues to evolve. Care for patients with metastatic disease, stage IVC, is focused on quality of life.
SUMMARY: Although occasional reports exist of long-term survivors with anaplastic thyroid carcinoma, the prognosis remains poor. Accurate staging is critical to offering the most appropriate treatment. Multimodality treatment is required if prolonged locoregional control or survival is desired.

Entities:  

Mesh:

Year:  2011        PMID: 21252667     DOI: 10.1097/MOO.0b013e328343af3d

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  23 in total

1.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

2.  Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.

Authors:  Zorica Milošević; Jasna Banković; Jelena Dinić; Chrisiida Tsimplouli; Evangelia Sereti; Miodrag Dragoj; Verica Paunović; Zorka Milovanović; Marija Stepanović; Nikola Tanić; Kostantinos Dimas; Milica Pešić
Journal:  Cell Oncol (Dordr)       Date:  2018-05-22       Impact factor: 6.730

3.  Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research.

Authors:  Mariavittoria Dima; Kelly A Miller; Valeria Gabriela Antico-Arciuch; Antonio Di Cristofano
Journal:  Thyroid       Date:  2011-07-18       Impact factor: 6.568

4.  Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma.

Authors:  Chuanzheng Sun; Chao Li; Zedong Hu; Xiaojiang Li; Jiehua He; Ming Song; Guojun Li; Fenghua Zhang; Qiuli Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-10       Impact factor: 2.503

Review 5.  Modeling anaplastic thyroid carcinoma in the mouse.

Authors:  Devora Champa; Antonio Di Cristofano
Journal:  Horm Cancer       Date:  2014-11-25       Impact factor: 3.869

6.  Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Paola Orlandi; Daniela Gentile; Marta Banchi; Greta Alì; Claudia Kusmic; Paolo Armanetti; Ginelle J Cayme; Luca Menichetti; Gabriella Fontanini; Giulio Francia; Guido Bocci
Journal:  Pharmacol Res       Date:  2020-05-24       Impact factor: 7.658

7.  Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.

Authors:  S Jang; X-M Yu; S Odorico; M Clark; R Jaskula-Sztul; C M Schienebeck; K R Kupcho; A D Harrison; G N Winston-McPherson; W Tang; H Chen
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

8.  Enlarging neck masses in the elderly - Histological and surgical considerations.

Authors:  M D O'Sullivan; K S McAnena; C Egan; P S Waters; P J McCann; M J Kerin
Journal:  Int J Surg Case Rep       Date:  2013-01-17

Review 9.  Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Authors:  P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré
Journal:  Clin Transl Oncol       Date:  2016-04-05       Impact factor: 3.405

10.  Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Alessandro Antonelli; Paola Orlandi; Silvia Martina Ferrari; Anna Fioravanti; Greta Alì; Gabriella Fontanini; Fulvio Basolo; Giulio Francia; Guido Bocci
Journal:  Cancer Lett       Date:  2017-09-28       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.